Results 71 to 80 of about 2,301 (144)

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 33-45, January 2026.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer

Antibodies, 2019
In the last decade, cancer immunotherapies have produced impressive therapeutic results. However, the potency of immunotherapy is tightly linked to immune cell infiltration within the tumor and varies from patient to patient.
Timothée Chanier, Patrick Chames
doaj   +1 more source

Trispecific SEED antibodies engineered for neutrophil-mediated cell killing

mAbs
Immunoglobulin (Ig) A has attracted interest as a proposed therapeutic agent due to its ability to engage cell groups differently compared to an IgG scaffold and elicit tumor eradication.
Veronica Natale, Gergely Heves, Katharina Stadlbauer, Florian Rüker, Vanessa Siegmund, Lukas Pekar, Stefan Zielonka, Lars Toleikis, Stefan Becker, Gordana Wozniak-Knopp   +9 more
doaj   +1 more source

Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L

mAbs
Multispecific antibodies (msAbs) are becoming more prevalent as formats of choice for therapeutic antibody development due to their ability to modulate multiple biological targets.
Kalie Mix, Tingwan Sun, Brian Hall, Jocelyn Newton, Christina Eng, Yongjing Guo, David Reczek   +6 more
doaj   +1 more source

Disentangling multispecific antibody function with graph neural networks

CoRR
16 pages, 5 figures, code available at https://github.com/prescient-design ...
Joshua Southern, Changpeng Lu, Santrupti Nerli, Samuel Don Stanton, Andrew M. Watkins, Franziska Seeger, Frédéric A. Dreyer   +6 more
openaire   +2 more sources

Single-domain antibodies as therapeutics for solid tumor treatment

Acta Pharmaceutica Sinica B
Single-domain antibodies (sdAbs), initially identified in camelids or sharks and commonly referred to as nanobodies or VNARs, have emerged as a promising alternative to conventional therapeutic antibodies.
Mingkai Wang, Tianlei Ying, Yanling Wu
doaj   +1 more source

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies

mAbs
Immunogenicity prediction is widely used in the developability assessment of antibodies, and many marketed and clinical-stage therapeutics have a predicted T-cell epitope in the second complementary-determining region of their light chain (CDR2L).
Maria U. Johansson, Anne Kerschenmeyer, Alessandra Carella, Simon Carnal, Yannik Schmidt, Alessandra de Felice, Dana Mahler, Marc Thomas, Fabio Mario Spiga, Julia Tietz, Christopher Weinert, Christian Hess, David Urech, Stefan Warmuth   +13 more
doaj   +1 more source

Antibodies and cryptographic hash functions: quantifying the specificity paradox

Frontiers in Immunology
The specificity of the immune response is critical to its biological function, yet the generality of immune recognition implies that antibody binding is multispecific or degenerate.
Robert J. Petrella, Robert J. Petrella
doaj   +1 more source

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. [PDF]

Biol Chem, 2022
Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch KG, Benz J, Ehler A, Lauer ME, Ringler P, Kobold S, Endres S, Klein C, Brinkmann U.   +16 more
europepmc   +1 more source

Development of Bispecific Antibody Targeting Human IL-17A and IL-6

Antibodies
Background/Objectives: Antibodies are a rapidly expanding field in drug discovery, but their monospecificity limits therapeutic applications, particularly in complex inflammatory diseases.
Beata Pamuła, Martyna Banach, Marta Mikońska, Karolina Korytkowska, Krzysztof Lacek, Oliwia Śniadała, Małgorzata Marczak, Krzysztof Flis, Aleksandra Sowińska, Damian Kołakowski, Jerzy Pieczykolan, Beata Zygmunt, Maciej Wieczorek, Olga Abramczyk   +13 more
doaj   +1 more source